An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model

Medicine and Dentistry

• Angiogenesis 25%
• Angiogenesis Assay 12%
• Angiogenesis Model 12%
• Antiangiogenic Activity 12%
• Body Weight 12%
• Body Weight Loss 12%
• Caffeine 12%
• Cells 25%
• Combination Therapy 37%
• Doxorubicin 50%
• Everolimus 12%
• Gelfoam 50%
• Lung 25%
• Lung Metastasis 12%
• Mammalian Target of Rapamycin 87%
• Mammalian Target of Rapamycin Inhibitor 12%
• Neoplasm 12%
• Osteosarcoma 100%
• Patient 100%
• Pazopanib 12%
• Tumor Necrosis 12%
• Tumor Progression 25%
• Vasculotropin Inhibitor 25%
• Xenograft 62%

Pharmacology, Toxicology and Pharmaceutical Science

• Caffeine 12%
• Doxorubicin 50%
• Everolimus 12%
• Gelfoam 50%
• Lung Metastasis 12%
• Mammalian Target of Rapamycin Inhibitor 12%
• Mouse Model 50%
• Neoplasm 12%
• Nude Mouse 25%
• Osteosarcoma 100%
• Pazopanib 12%
• Tumor Growth 25%
• Tumor Necrosis 12%
• Vasculotropin Inhibitor 25%

Biochemistry, Genetics and Molecular Biology

• Angiogenesis 50%
• Antiangiogenic Activity 12%
• Body Weight 12%
• Body Weight Loss 12%
• Doxorubicin 50%
• Fluorescence 25%
• Growth 25%
• Length 25%
• Mouse Model 50%
• Nude Mouse 25%
• Pazopanib 12%
• Time 12%
• Tumor Volume 12%
• Vascular Endothelial Growth Factor 25%